Third, fourth, fifth, sixth, seventh ... ... the end of the voice, the eighth again!
On December 14, a batch of Qilu pharmaceutical oral preparations - olanzapine tablets were shipped from the Qilu Pharmaceutical Group Jinan High-tech Factory to the United States, which was the eighth pharmaceutical product exported to the United States by Qilu Pharmaceutical Co., Ltd., which filled the domestic exports to the United States Just a week ago, 90,000 irinotecan injections were shipped from Qilu Pharmaceutical (Hainan) Co., Ltd. to the United States; two months ago, the sixth formulation was shipped to the United States ... 2017 is undoubtedly Qilu Especially for the United States, which is the internationally recognized market with the highest quality and highest standards of drug quality. From the beginning of the year to the end of the year, the company added 6 new products to its 2 products in 2016, Enough to reflect the overall strength of enterprises.
It is worth mentioning that access to FDA certification is a prerequisite for the preparations to enter the US market, and the FDA's regulatory standards have also been identified by the World Health Organization as the highest food and drug safety standards. As of now, Qilu Pharmaceutical Group has received a total of 9 FDA product certification , The future performance in the U.S. market continues to be optimistic.
Over the years, Qilu Pharmaceutical has been unswervingly advancing the strategy of internationalization. As China continues to deepen its participation in the division of labor in the international pharmaceutical industry, Qilu Pharmaceutical has been steadily upgrading its position to the top of the international pharmaceutical industry value chain and expanding its exports from pharmaceutical raw materials to preparations In recent years, the high-end formulations of the company continue to achieve breakthroughs in the high-end market, including the United States, Britain, Germany, Japan, is a microcosm of the results of this internationalization strategy continues to bloom.In the United States, Qilu Pharmaceutical to 2016 In March, 4,400,000 ondansetron hydrochloride injections started the export to the United States, and eight products that have been exported to the United States in succession, covering the two major fields of anti-tumor and anti-infectives, of which 6 new products were added this year, And the amount showed a blowout growth.Export terms, so far, has more than 9 million US dollars, the annual figure will exceed 10 million US dollars, an increase of more than 500% .In addition to the triumphant triumph of the United States exports all the way, Qilu Pharmaceutical this year The export of preparations in Japan, the European Union, Australia, New Zealand, South Africa, Ukraine and other countries and regions also maintained a good momentum. It is estimated that the annual export volume will reach 350 0 million US dollars.
It is worth mentioning that more than one single product Qilu pharmaceutical in the United States, Japan, Australia, New Zealand and other places more than 50% market share. The company is currently the only one to achieve the export of Japanese aseptic agents. The main benefit In the company's industry-leading quality control system and management system, the company always maintain the superiority of product quality.Qilu Pharmaceutical also thus with a number of the world's pharmaceutical giant, maintained a broad and stable cooperative relations.
